EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitSystematische ÜbersichtMetaanalyseOpen Access · CC BY 4.0

Metastatic Colorectal Cancer Beyond Third-Line Treatment: Systematic Review and Meta-Analysis of Later-Line Therapies

Jacopo Giuliani iD, Emilia Durante, Daniela Mangiola, Andrea Georgopulos iD, Beatrice Mantoan, Francesco Fiorica iD

Journal of Clinical Medicine · 20.04.2026 · 15 (8) · 3128

DOI: 10.3390/jcm15083128 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Clinical Medicine, online erschienen am 20.04.2026. Verfasst von Jacopo Giuliani und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Oncology, Section of Medical Oncology, AULSS 9 Scaligera, 37045 Legnago, Italy. Die Arbeit nennt 14 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

To evaluate and indirectly compare overall survival (OS) and safety of regorafenib, fruquintinib, and trifluridine/tipiracil (TAS-102) monotherapy in refractory metastatic colorectal cancer (mCRC) beyond the third line.

Methods

A systematic review and meta-analysis of phase II/III randomized controlled trials was conducted according to PRISMA guidelines. PubMed/MEDLINE, Embase, and Cochrane CENTRAL were searched from inception. Eligible studies included patients with mCRC previously treated with standard chemotherapy and biologic agents, receiving regorafenib, fruquintinib, or TAS-102 as monotherapy in the fourth line or later. OS data were reconstructed from published Kaplan–Meier curves. Pooled median and mean OS were estimated using a random-effects model, and heterogeneity was assessed using the I2 statistic. Safety outcomes were descriptively summarized.

Results

Four RCTs were included. The pooled median OS was 7.83 months (95% CI: 6.98–8.80), and the pooled mean OS was 8.90 months (95% CI: 8.00–9.81), with no heterogeneity (I2 = 0%). Survival gains versus placebo ranged from 1.4 to 2.6 months. Survival curves largely overlapped, with differences below one month. Safety was consistent with known profiles.

Conclusions

These agents provide comparable efficacy with modest survival benefit in late-line mCRC, highlighting the need for improved strategies and better treatment sequencing.

Schlagwörter

Stichwörter der Autor:innen

fruquintiniblate-line therapymetastatic colorectal canceroverall survivalregorafenibsystematic reviewtrifluridine/tipiracil

Autor:innen und Institutionen

  • Department of Clinical Oncology, Section of Medical Oncology, AULSS 9 Scaligera, 37045 Legnago, Italy.
  • Department of Clinical Oncology, Section of Radiation Oncology and Nuclear Medicine, AULSS 9 Scaligera, 37045 Legnago, Italy.
  • Department of Diagnostic Imaging, AULSS 9 Scaligera, 37045 Legnago, Italy.

ORCID-Profile: Jacopo Giuliani, Andrea Georgopulos, Francesco Fiorica

Zitieren

APA

Giuliani, J., Durante, E., Mangiola, D., Georgopulos, A., Mantoan, B., & Fiorica, F. (2026). Metastatic Colorectal Cancer Beyond Third-Line Treatment: Systematic Review and Meta-Analysis of Later-Line Therapies. Journal of Clinical Medicine, 15(8), 3128. https://doi.org/10.3390/jcm15083128

Vancouver

Giuliani J, Durante E, Mangiola D, Georgopulos A, Mantoan B, Fiorica F. Metastatic Colorectal Cancer Beyond Third-Line Treatment: Systematic Review and Meta-Analysis of Later-Line Therapies. Journal of Clinical Medicine. 2026;15(8):3128. doi:10.3390/jcm15083128

BibTeX
@article{Giuliani2026,
  author = {Giuliani, Jacopo and Durante, Emilia and Mangiola, Daniela and Georgopulos, Andrea and Mantoan, Beatrice and Fiorica, Francesco},
  title = {Metastatic Colorectal Cancer Beyond Third-Line Treatment: Systematic Review and Meta-Analysis of Later-Line Therapies},
  journal = {Journal of Clinical Medicine},
  year = {2026},
  volume = {15},
  number = {8},
  pages = {3128},
  doi = {10.3390/jcm15083128}
}
Kostenlos starten →